Roche Novartis AGCM Hoffmann Misleading 101 Astra Zeneca Court of Justice CJEU

The CJEU has just confirmed that the concerted provision of misleading information about product safety can constitute a restriction by object under Article 101(1) TFEU, when it is intended to reduce the competitive pressure resulting from an alternative medicinal product (Case C-179/16, F. Hoffmann-La Roche and Others v Autorità Garante della Concorrenza e del Mercato).
Continue Reading Breaking news: CJEU ruling in Hoffmann-La Roche published on 23 January